EXPEDITING THE PATH
TO PATIENTS

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease that can lead to cirrhosis, liver failure, and the need for transplantation. Current approved treatments benefit only a small percentage of patients, and many late-stage therapies have shown only modest improvements.

TGM-312 is being developed to target steatosis, inflammation, and fibrosis, with the potential for patient-friendly quarterly dosing. In preclinical studies using a highly translatable model of MASH, TGM-312 significantly reduced liver fat accumulation, inflammation, and markers of fibrosis. TGM-312 showed strong monotherapy activity and synergistic effects in combination with approved and emerging therapies, supporting its potential to treat disease across multiple stages and bring benefit to a broad range of patients.

TGM-291 is being developed for people living with cardiometabolic diseases such as Type 2 Diabetes, cardiovascular disease and metabolic syndrome, which remain the leading cause of illness and mortality worldwide. Current therapies focus largely on LDL-C lowering, but many patients continue to face high residual risk. TGM-291 targets a gene with strong human genetic validation and, in preclinical studies, has shown pleiotropic benefits across multiple risk factors including insulin sensitivity, cholesterol, and fibrinogen, showing its potential to impact the residual cardiovascular risk that remains after LDL-C lowering.

TGM-258 is being developed as a novel therapy for heart failure (HF), a leading cause of death and hospitalization worldwide that affects more than 6 million Americans today. Despite several approved medicines being available, many patients discontinue treatment within the first year due to complex treatment regimens and severe side effects. In preclinical models of heart failure, TGM-258 improved cardiac output and ejection fraction, and reduced fibrosis. With the potential for infrequent dosing and improved adherence, TGM-258 aims to deliver safer, more effective outcomes for people living with heart failure.

Bleeding disorders affect around 8 million people worldwide, causing uncontrolled bleeding episodes, joint damage, and reduced quality of life. While treatments for hemophilia have advanced, people with other bleeding disorders, such as von Willebrand Disease, still face limited options, high treatment burden, and inconsistent care.

TGM-148 is being developed as a universal hemostatic agent that can provide safe, low-burden protection across multiple bleeding disorders. In preclinical models of four different bleeding disorders, TGM-148 significantly improved clotting parameters and reduced bleeding events. Importantly, these benefits were achieved without signs of increased thrombosis risk. With a convenient subcutaneous regimen of just four doses a year, TGM-148 has the potential to offer a safe and effective treatment across bleeding disorders.

TGM-148 is on track for a regulatory submission and clinical entry during 2026.

TGM-407 is being developed as a patient-friendly therapy for dry age-related macular degeneration (Dry AMD), the leading cause of blindness worldwide. Current treatments rely on highly invasive intravitreal injections (IVT), which place a major burden on patients. Sparing IVT, TGM-407 aims to change this with a convenient subcutaneous regimen of just four doses a year, targeting a liver-expressed gene with human genetic evidence linking it to disease pathology in the eye. In preclinical studies, TGM-407 reduced expression of the target gene in the liver, which was tightly correlated with decreased target protein levels in the eye, providing strong validation for this therapeutic approach. TGM-407 has also demonstrated safety in toxicology studies, reinforcing its potential as a safe and transformative therapy for people with Dry AMD.